SCHEMBL1748413

SCHEMBL1748413

COc1cc2c(-c3cc4cccnc4[nH]3)cn(CCN3CCCN(C)CC3)c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.63
HTR7 P34969 3/20 0.40
RIPK1 Q13546 3/20 0.40
SYK P43405 1/20 0.40
CLK2 P49760 2/20 0.39
DYRK1A Q13627 2/20 0.39
CLK3 P49761 1/20 0.39
CHKA P35790 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
KDR P35968 2/20 0.37
FLT3 P36888 1/20 0.37
MKNK2 Q9HBH9 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749006 0.96 IGF1R (0.67) IGF1RRIPK1SYKCLK2DYRK1A
SCHEMBL1748879 0.95 IGF1R (0.61) IGF1RRIPK1SYKCLK2DYRK1A
SCHEMBL1748897 0.90 IGF1R (0.65) IGF1RRIPK1SYKCLK2DYRK1A
SCHEMBL1779928 0.89 IGF1R (0.66) IGF1RRIPK1SYKCCNB2CDK1
Trifluoroacetic Acid SCHEMBL1748997 0.88 IGF1R (0.53) IGF1RRIPK1SYKDRD2DRD3
SCHEMBL27668972 0.87 IGF1R (0.62) IGF1RRIPK1SYKDRD2DRD3
SCHEMBL1748415 0.87 IGF1R (0.69) IGF1RSYKDNMT1EHMT2
SCHEMBL27687994 0.87 IGF1R (0.59) IGF1RRIPK1SYKEHMT2
SCHEMBL27687971 0.86 IGF1R (0.61) IGF1RRIPK1SYKDRD2DRD3
SCHEMBL1749108 0.85 IGF1R (0.59) IGF1RRIPK1SYKCCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885HTR7 2716/4885RIPK1 392/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885HTR7 2716/4885RIPK1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.